Rigel Pharmaceuticals, Inc. (RIGL) Reports Q3 Loss of $0.25
RIGL Hot Sheet
EPS Growth %: +20.0%Financial Fact:
Basic (in shares): 71.42M
Today's EPS Names:
TARO, BRLI, TLB, More
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q3 EPS of ($0.25), versus $0.96 reported last year. Revenue for the quarter came in at $4.35 million, versus $72.28 thousand reported last year.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- VeriFone Systems (PAY) Tops Q2 EPS by 3c; Guides Q3, FY12
- Taro Pharmaceutical Industries (TARO) Nearly Doubles Q1 EPS to 1.06
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
